Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery…
Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year. Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an...
PR Newswire
04/06/2025
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar…
Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane Biopharma AB (“Xbrane”), with the acqusition of the R&D organization of Xbrane in Sweden and biosimilar candidate to Cimzia® (certolizumab pegol). All regulatory conditions have been fulfilled.The transaction, which was announced on March 20, 2025, and approved by Xbrane's Extraordinary...
Nasdaq GlobeNewswire
04/06/2025
Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to…
"We are thrilled to advance our clinical trials by integrating Veeva Clinical Platform into our digital toolkit," said SCRI chief information and digital officer Yazhene Krishnaraj. "This strategic collaboration empowers our clinical teams to deliver groundbreaking therapies to patients with enhanced precision and speed." "We are thrilled to advance our clinical trials by integrating Veeva Clinical Platform into our digital toolkit," said SCRI chief information and…
PR Newswire
04/06/2025
Research Grid's artificial intelligence automates a 3-year Queen Mary clinical…
Over 80% of medical research data globally is still entered manually by highly qualified research staff, slowing progress and driving up costs. Research Grid's patented AI changes that by safely handling complex clinical trial admin of every kind. For example, handwritten text, numbers, images and anonymization while performing quality checks. Over 80% of medical research data globally is still entered manually by highly qualified research staff, slowing progress and driving up costs…
PR Newswire
04/06/2025
MolecuLight to Showcase Innovative Wound Imaging Platform at the Society for…
In addition to its presence on the exhibition floor, MolecuLight is proud to highlight that Dr. Alisha Oropallo has received the Society for Vascular Surgery Section on Ambulatory Vascular Care (SAVC) Presentation Award for her abstract titled, "An objective comparative study of non-surgical cleansing techniques and cleanser types in bacterial burden management." Dr. Oropallo will be presenting her award-winning research during the VAM SAVC session on Friday, June 6th. This study…
PR Newswire
04/06/2025
Accumulus Synergy and Veeva Systems Partner to Advance Regulatory Transformation…
“Our partnership with Veeva is an important step forward in enabling our collective customers to maximize the benefit of the two technologies - Accumulus' single dossier in the cloud and Veeva's comprehensive Regulatory Information Management (RIM) platform,” said Francisco Nogueira, CEO of Accumulus. “At Accumulus, we have seen tremendous cycle time improvements driven by our platform. Through this partnership, we're poised to significantly increase organizational efficiency for our...
Nasdaq GlobeNewswire
04/06/2025
SciBase Expands Further Through European Market with First Sales Order to…
"I am very proud to be part of a lifesaving project to address the critical issue of melanoma in Italy. I firmly believe Kilabs will play a crucial role in securing appropriate deployment of Nevisense thanks to our high expertise and introduction in the field", says Michelangelo Simonelli CEO of Kilabs Srl. " I am very proud to be part of a lifesaving project to address the critical issue of melanoma inItaly. I firmly believe Kilabs will play a crucial role in securing appropriate…
PR Newswire
04/06/2025
Midea becomes Global Supporter of the AFC's National Team Competitions
In 2027, Midea will also be present as a global supporter at the AFC Asian Cup Saudi Arabia 2027™. It will be the first time the competition has been held in Saudi Arabia in what promises to be a historic event. In 2027, Midea will also be present as a global supporter at the AFC Asian Cup Saudi Arabia 2027™. It will be the first time the competition has been held inSaudi Arabiain what promises to be a historic event. "The next four years are set to be an important part of AFC's...
PR Newswire
04/06/2025
Commit Biologics appoints leading industry experts to newly formed Scientific…
The SAB will provide constructive feedback to Commit's management team and Board of Directors as the Company further develops its Bispecific Complement Engager (BiCE™) technology platform. The SAB will provide constructive feedback to Commit's management team and Board of Directors as the Company further develops its Bispecific Complement Engager (BiCE™) technology platform. Mikkel Wandal Pedersen, PhD, Chief Executive Officer of Commit Biologics, said: "Forming Commit's Scientific...
PR Newswire
04/06/2025
Sobi Showcases Breadth of data in C3G/primary IC-MPGN at ERA 2025
The two abstracts selected in the top 10 at the conference both highlight important subgroup results from the randomised-controlled-period (RCP) of the VALIANT Phase 3 study covering the treatment effect of pegcetacoplan at 26 weeks in patients with nephrotic range proteinuria at baseline, and the effect of pegcetacoplan in adolescents at 26 weeks. The two abstracts selected in the top 10 at the conference both highlight important subgroup results from the randomised-controlled-period (RCP)…
PR Newswire
04/06/2025
ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT MAY 2025
Accumulated revenue for January – May 2025 increased by 57 % to SEK 1,261.7 (805.6) million. Accumulated revenue for January –May 2025increased by 57 % toSEK 1,261.7(805.6) million. Revenues were distributed as follows: Countries in regions: -The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden - Central Europe :Austria,Germany,Switzerland - East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania -South &...
PR Newswire
04/06/2025
Philips to repurchase up to 6 million shares to cover long-term incentive plans
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive plans. At the current share price, the shares represent an amount of up to approximately EUR 125 million.The repurchases will be executed through one or more individual forward transactions, to be entered into in the course of the second and third quarter of 2025, in accordance with...
Nasdaq GlobeNewswire
04/06/2025
Duni launches new take-away series with improved recyclability and enhanced…
- With Vista, we are taking an important step toward offering our customers more sustainable and functional packaging solutions that are designed for real-world needs. The grey plastic allows for recycling in a way that black plastic does not, while the enhanced features contribute to a better user experience from kitchen to consumer. This innovation supports higher recycling rates and reduced plastic use and is a key milestone in Duni Group's journey toward a circular future, says Caroline…
PR Newswire
04/06/2025
Implantica announces that UK NICE has published positive recommendations for the…
Mr. Ahmed Ahmed, Consultant Surgeon at St. Mary's Hospital, Imperial College NHS Health Trust says, "The positive NICE guidance for use of RefluxStop is a major victory for GORD patients. This decision empowers NHS Anti-Reflux Surgeons to continue delivering cutting-edge care while contributing to the growing body of evidence supporting RefluxStop procedure as a transformative solution for GORD. My patients have heard about RefluxStop procedure as they seek a solution for GORD and ask for…
PR Newswire
04/06/2025
Ex dividend NOK 1.25 today
The shares in Vistin Pharma ASA (VISTN) will be traded ex dividend NOK 1.25 as from today, 04.06.2025.
Nasdaq GlobeNewswire
04/06/2025
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge…
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilitiesLondon,4 June 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreement with Bayer HealthCare LLC, granting LIfT access to Bayer's state-of-the-art Co.Lab facilities in Cambridge, Massachusetts – one of the world's leading hubs for biotech innovation.This agreement...
Nasdaq GlobeNewswire
04/06/2025
Ose Immunotherapeutics : Documents made available to the shareholders for the…
Documents made available to the shareholders for the combined general meeting of June 25 th, 2025Nantes, June 4 th, 2025, 8 a.m.- OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnemo: OSE)announces the publication of the preparatory documents for the combined general meeting to be held on June 25 th, 2025 at 10 a.m. at the Drawing House Hotel - 21, rue Vercingétorix - 75014 Paris.The convening notice ( avis de reunion valant avis de convocation ) containing the...
Nasdaq GlobeNewswire
04/06/2025
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of…
OSE Immunotherapeutics strengthens Growth Strategy:Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology & inflammation pipelinethrough lusvertikimab development, leveraging a new predictive biomarker. Leads a new era in cancer vaccineswith Tedopi® on track for registration. Drives company transformation through responsible governance:international development, rigorous financial planning and clinical execution.NANTES,...
Nasdaq GlobeNewswire
04/06/2025
Valneva Announces Availability of Documentation for its Combined Shareholder…
Saint-Herblain (France), June 4, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined General Meeting (“the Meeting”) to be held on June 25, 2025 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France). The Preliminary Notice of Meeting – including the agenda, the draft resolutions proposed by the Board of Directors, and...
Nasdaq GlobeNewswire
04/06/2025
Roche's Evrysdi tablet approved by European Commission as first and only for…
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers the same efficacy and safety demonstrated in available oral solution Evrysdi is the only non-invasive disease-modifying SMA treatment, with more than 18,000 people with SMA treated globally to dateBasel, 04 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved a label extension...
Nasdaq GlobeNewswire
04/06/2025
World's Leading Institutions and IBA launch Proton Therapy Academy to shape the…
New global education initiative unveiled at 2025 PTCOG Annual ConferenceLouvain-la-Neuve, Belgium, 4 June 2025- IBA (Ion Beam Applications SA), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces the launch of Proton Therapy Academy, a new global training and education initiative developed in partnership with prominent institutions in the field of proton therapy. The Academy has...
Nasdaq GlobeNewswire
04/06/2025
Telix's Illuccix® PSMA-PET Imaging Agent Approved in Portugal
PSMA-PET imaging represents a significant advancement in prostate cancer management, largely replacing conventional imaging methods such as bone scans and CT[4] scans as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines recognise its superior accuracy in staging primary disease and assessing BCR[5]. Illuccix® PSMA-PET will help address an important clinical need by supporting timely and effective diagnosis, as well as identifying patients who may…
PR Newswire
04/06/2025
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin'…
SEOUL, June 4, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. SEOUL , June 4, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOsSeongsoo Parkand...
PR Newswire
04/06/2025
Essential Thrombocythemia Market to Witness Robust Growth During the Forecast…
As of 2024, approximately 167K individuals in the US were diagnosed with essential thrombocythemia, with about 75% of these cases linked to mutations in the JAK2 gene. During the same year, an estimated 85K patients in the US received first-line treatment for essential thrombocythemia. As of 2024, approximately 167K individuals in the US were diagnosed with essential thrombocythemia, with about75%of these cases linked to mutations in the JAK2 gene. During the same year, an estimated ...
PR Newswire
03/06/2025
Altri Comunicati
